Introduction {#s1}
============

The mitochondrial permeability transition pore (MPTP) complex is a non-specific and -selective channel composed of multiple proteins, which is voltage-dependent and spans cytoplasm, outer mitochondrial membrane (OMM), inner mitochondrial membrane (IMM), and mitochondrial matrix. Excessive MPTP opening has been reported in relation to myocardial ischemia reperfusion injury ([@B83]), hepatic ischemia-reperfusion injury ([@B88]), traumatic brain injury ([@B41]), premature aging ([@B177]), and Parkinson's disease ([@B73]). However, its structural composition of MPTP ([@B8]) and detailed regulatory mechanism in ischemic stroke are still poorly understood. To our knowledge, current evidences support the fact that MPTP is composed of voltage-dependent anion channel (VDAC) across the OMM, adenine nucleotide translocator (ANT) in the IMM, and cyclophilin D (CypD) in the mitochondrial matrix, which is responsible for sensing intracellular environmental oxidative stress injury, inflammatory cascade, pH imbalance, and ion disorders such as Ca^2+^ and Mg^2+^ ions in response to tissue ischemia ([@B48]; [@B15]). These adverse factors, alone or together, can force persistent and irreversible MPTP opening beyond the range of physiological regulation, and thus inducing mitochondria-dependent apoptotic events. In addition, cytoplasmic hexokinase II (HK II) attached to VADC, the peripheral benzodiazepine receptor (PBR) on OMM and creatine kinase responsible for ATP production may be involved in the formation or regulation of MPTP ([@B153]). Possibly as a component of IMM and binding partner of CypD, the phosphate carrier (PiC) of mitochondria is responsible for the supply of inorganic phosphates required by ATP synthesis during oxidative phosphorylation of mitochondria ([@B14]; [@B10]; [@B105]). However, whether PiC has a positive or negative effect on the structure and function of MPTP, it is still a matter of debate and disagreement. [**Figure 1**](#f1){ref-type="fig"} illustrates the canonical molecular composition of MPTP.

![Canonical mitochondrial MPTP molecular structure. Conventional MPTP complex is composed of VDAC, ANT, and CypD. Other factors could also stimulate MPTP opening.](fphar-11-00352-g001){#f1}

In recent years, several other members involved in MPTP regulation responsible for cell fate decision have also been identified in succession. As one of the core components of IMM, RNAi-targeted silencing of the spastic paraplegia 7 gene blocked signal transmission between OMM and mitochondrial matrix by indirectly associating VDAC with CypD in the matrix, thereby abrogating overloaded Ca^2+^ and immoderate ROS evoked mitochondrial membrane potential (MMP) decline and MPTP-dependent cell death ([@B100]). Except for the re-confirmation that ANT was the basic intimal component of MPTP, researchers had also found that other CypD-dependent components were involved in the composition of MPTP. Although the species destined for existence had not yet been identified, the authors suggested that PiC such as the *Slc25a3* or F~1~F~O~ ATP synthase may be involved, which still needed to be explored in a reasonable and rigorous *in vivo* and *in vitro* experiment ([@B49]). Further encouraging evidence suggested that F-ATP synthase was involved in the formation of MPTP, sensing Ca^2+^ concentration and subsequently mediating MPTP opening ([@B114]). As the structure and functions of MPTP are gradually clarified, great quantities of studies have declared that abnormal MPTP conditions play a critical role in regulating cell fate in a variety of diseases. The VDAC has virtually no barrier effect on small molecules with molecular weights less than 5 kDa to circulate freely in the cytoplasm and mitochondrial matrix ([@B11]). As an intermediate bridge, ANT can interact directly with VDAC and CypD. And that is, ANT can alter OMM and IMM permeability by regulating VDAC and CypD, thus mediating the exchange of substances in the cytoplasmic matrix and the mitochondrial matrix ([@B28]). In a mouse model of heart failure, it had been substantiated that increased mitochondrial matrix Ca^2+^ caused by *Ppif* gene (encoding the synthesis of CypD protein) deficiency contributed to the remission of heart failure symptoms ([@B38]). By further silencing CypD gene with *in vitro* siRNA and shRNA techniques on primary human pulmonary artery endothelial cells, and *in vivo* CypD knockout mice, evidence of CypD deficiency had been shown to promote angiogenesis, which may be partly due to increased mitochondrial matrix Ca^2+^ and nicotinamide adenine dinucleotide (NADH), activation of NAD^+^-dependent deacetylase sirtuin 1 (SIRT1) and serine-threonine kinase Akt signaling ([@B76]). Evidence suggested that induced pluripotent stem cells (iPSCs) derived hepatocyte toxicity caused by valproic acid was associated with MPTP opening dependent mitochondrial apoptotic pathway ([@B61]).

Causality Between Abnormal MPTP Opening and Apoptosis in Ischemic Stroke {#s1_1}
------------------------------------------------------------------------

Abnormalities of MPTP state are bound to trigger cellular dysfunction in ischemic stroke. We will briefly summarize the factors and related molecular mechanisms of MPTP opening-induced apoptosis after ischemic stroke. A large number of previous reports have shown that stroke-evoked decreased MMP, excessive mitochondrial reactive oxygen species (mtROS) ([@B181]), endoplasmic reticulum stress (ERS), and excitatory amino acid toxicity all stimulated MPTP opening ([@B92]), leading to mitochondrial edema, increased membrane permeability, corrupted cristae structure of IMM, and neuronal apoptosis. Notably, as the second messenger, Ca^2+^ is a stimulus of MPTP opening and also could be a landmark event after MPTP opening. However, from the actual effect, increased Ca^2+^ and depressed matrix Mg^2+^ and Mn^2+^ could all contribute to MPTP opening. In turn, evidence had announced that instantaneously MPTP opening could cause increased Ca^2+^ in microdomain of astrocytes, which was closely related to maintaining mitochondrial energy supply and stress response ([@B1]). The otherwise MPTP opening-prone factors are as following. Declined matrix PH, caused by protonation of histidine residues or loss of ANT and CypD signaling, could trigger MPTP to tend to shut down. Conversely, the increased matrix PH forces MPTP opening with its maximum openness at about 7.3 ([@B123]; [@B102]). The formation of disulfide by oxidation on ANT dimer, oxidized pyridine nucleotides such as NAD^+^ and NADP^+^ all favor MPTP openness. Conversely, all the factors that inhibit MPTP opening may have a promising future in treating ischemic stroke. Ligands targeting VADC, ANT, CypD ([@B77]), and TSPO/PBR targets have shown better inhibition of MPTP opening. Moreover, antioxidants such as propofol, metabolites such as glucose and creatine, coenzyme Q, glutamate, or Ca^2+^ chelators could limit MPTP opening ([@B153]; [@B14]).

It is well known that onset of ischemic stroke causes neurons to produce exorbitant mtROS, ERS, Ca^2+^ overload, and neuronal toxicity induced by excitatory amino acids. After that, neurons would raise the alarm of MMP decline, mitochondrial edema, elevated MMP and other signs of MPTP opening, which will eventually drive mitochondrial contents such as Cyto-c to be discharged into the cytoplasm and trigger apoptotic events. The results of *in vivo* animal evaluation have intimated that both transient and permanent cerebral ischemic insults can cause damage to mitochondrial ultrastructure of neuron, such as the appearance of swollen and condensate mitochondria, as well elevated matrix density caused by deposition of electron-dense material ([@B104]). An ischemia-induced ROS elevation can favor MPTP opening, which in turn can lead to a subsequent surge in ROS production and a vicious cycle ([@B181]). Therefore, inhibition of neuronal apoptosis by blocking MPTP opening would be a potential and promising strategy in the treatment of ischemic stroke. Further extensive *in vivo* and *in vitro* experimental evidence also suggested a positive effect of this therapy. In rat models of ischemic stroke, blocking MPTP opening by cyclosporine A had been shown to reduce infarcted volume of ischemic brain tissue ([@B77]). As a ligand targeting CypD, pre-administration of cyclosporine A can protect primary rat neurons from OGD/R injury, involved mechanisms may be related to maintain mitochondrial integrity and inhibit MPTP opening-induced apoptosis by up-regulating Parkinson's disease-associated protein DJ-1 ([@B112]). Further, the water-soluble coenzyme Q10 had been shown to protect the accumulation of glutamate-induced HT22 hippocampal neuron damage by inhibiting mitochondrial fragmentation and MPTP opening-induced apoptosis ([@B54]). Furthermore, evidence had shown that intervention of MPTP opening inhibitor can reduce the expression of VDAC, manifesting by increased MMP, ATP supply, and improved cerebral ischemia injury symptoms in an *in vitro* rat model of MCAO ([@B125]). The above evidence all conveys that ischemic stroke induced MPTP opening may be a factoid of neuronal apoptosis. Any measures to inhibit MPTP opening could repress cell apoptosis, thus exhibiting the role of anti-ischemic brain protection.

Explosive evidence corroborated that a sudden insult of ischemic stroke may break the balance between the anti-apoptotic and pro-apoptotic members of B-cell lymphoma-2 (Bcl-2) family, which may aggravate stroke condition. The results of ischemic stroke models with Bax gene knockout *in vivo* and *in vitro* showed that the improved ischemic neuron injury and decreased neuronal apoptosis were related to the decreased cytoplasmic Ca^2+^, which was a relatively upstream signal regulating the apoptosis of ischemic neurons ([@B32]). A great deal of evidence has declassified such a fact that anti-apoptotic Bcl-2 and Bcl-x~L~ can inhibit MPTP opening, whereas pro-apoptotic Bax and Bak proteins can stimulate MPTP opening ([@B33]). Results from *in vitro* model of ischemic stroke in rats have shown that increased Bax/Bcl-2 ratio in ischemic insult could irritate MPTP opening, which may cause increased neuronal apoptosis ([@B3]; [@B4]). Actually, members in Bcl-2 family could also regulate two potential MPTP opening stimuli: Ca^2+^ homeostasis and energy metabolism of neurons ([@B33]; [@B91]). The increased permeability caused by the formed Bax/Bak dimer on OMM contributed to the release or transfer of pro-apoptotic Cyto-c, Smac/Diablo and HtrA2/Omi from the mitochondrial matrix to cytoplasm ([@B5]). Further rat models of focal cerebral ischemia also demonstrated that overexpressed Bcl-2 protein could inhibit the rise of Cyto-c in cytoplasm, thereby preventing the occurrence of apoptotic DNA fragmentation events mediated by the transfer of AIF from mitochondria to nucleus ([@B165]). While pro-apoptotic Bcl-x~S~-induced apoptosis via Bak also induced the exudation of mitochondrial Cyto-c, the formation of apoptosome composed of Cyto-c, Apaf-1 and Caspase-9, and the Caspase apoptotic cascade ([@B66]; [@B162]). Visually breaking news, Bak/Bax macropores contribute to the outflow of mitochondrial contents such as Cyto-c and mitochondrial DNA into the cytoplasm, and thereafter inducing caspase-dependent cell apoptosis ([@B79]). Amusingly, evidence also suggested that ROS and ERS could directly activate Bak/Bax-dependent apoptosis, showing condensed and hyperchromatic nucleus, loss of MMP, reduced Bcl-2, increased activation of Caspase-3/-9, PARP, and overexpressed Bak and Bax proteins ([@B99]). Therefore, the formation of Bak/Bax macropores in mitochondrial OMM may serve as a hub for MPTP opening-induced mitochondrial apoptosis. Other factors involved in the regulation of MPTP opening after cerebral ischemia have also been reported. Accumulation of p53 in mitochondria has been corroborated to target CypD, leading to MPTP opening and neuronal apoptosis, which is independent of the formation of Bak/Bax macropores ([@B115]). It has been reported that activation of neuron mitochondrial cannabinoid receptor 1 after cerebral ischemia can help inhibit Ca^2+^ overload-induced MPTP opening and apoptosis ([@B17]). Another potential target involved in regulating mitochondrial MPTP in ischemic stroke was mitochondrial uncoupling protein 2 (UCP-2). Highly expressed UCP-2 has been demonstrated to inhibit apoptosis by activating redox signaling, evidenced by decreased ROS production, increased MMP and cleaved Caspase-3 protein expression ([@B78]; [@B80]). The above analysis indicates that ischemic stroke is accompanied by an inevitable event of MPTP over-opening and apoptosis. Although the basic structure of MPTP has not yet been drastically uncovered and recognized. But a number of factors that regulate MPTP opening during the course of ischemic stroke have been exposed in the public eye. In the future, plenty of basic studies should be conducted to elucidate the molecular composition of MPTP and its relationship with ischemic neuron apoptosis. Meanwhile, natural product inhibitors targeting MPTP opening-evoked neuronal apoptosis are also worthy of further research in the treatment of ischemic stroke.

Progress in Stroke Prevention and Treatment by Regulating Mitochondrial MPTP Status in Ethnic Medicine {#s2}
======================================================================================================

Ischemic stroke, which accounts for 71% of stroke, is the second and the first leading cause of death and disability worldwide and in China, respectively ([@B140]). In 2016, there were 9.5 million ischemic stroke patients worldwide, while in 2017, 2.7 million people died of ischemic stroke ([@B18]). Although intravenous thrombolysis, antiplatelet aggregation, and anticoagulant therapy ([@B103]; [@B106]) could be used for the delivery of stroke therapies, but many apoplexy sequelae, characterized by ischemic contralateral or bilateral limb behavior disorders, memory decay, logopathy, dysphagia, and mood irritability ([@B169]; [@B45]), have not yet cure. However, the ethnic medicine has manifested significant clinical efficacy in alleviating above unbearable symptoms or sequelae of stroke. In recent years, the mechanisms of action of drugs have also been gradually revealed. Remarkably, some of them, such as Danhong injection and Naoxintong capsule ([@B42]; [@B67]; [@B143]), have been officially approved by the China Food and Drug Administration (CFDA) and are bringing good news to stroke patients around the world. Next, we summarized the current officially authorized products, clinically effective traditional Chinese medicine (TCM) prescriptions, ethnic drugs, and effective monomer components based on literature review, trying to clarify the molecular mechanisms of natural products inhibiting neuronal apoptosis and improving ischemic brain from the perspective of mitochondrial MPTP.

Authorized Products for Stroke Improvement by Regulating Mitochondrial MPTP {#s2_1}
---------------------------------------------------------------------------

With the policy guidance and inclination, as well as the accelerated modernization of TCM, tens of thousands of individuals dedicated to clinical and scientific research positions are gradually devoting themselves to the drug development and mechanism exploration of traditional medicine to prevent major diseases, such as stroke. Most ethnic drugs for treatment of ischemic stroke have the function of activating blood circulation to remove blood stasis or clear collaterals. NaoShuanTong capsule ([@B161]), ShenQi Fuzheng injection ([@B16]), ShengMai injection ([@B145]), and PeiYuan TongNao capsule ([@B6]) have been reported to significantly improve the symptoms of ischemic stroke with few adverse events. In recent years, some antiapoptotic protective effects of cerebral ischemia have also been reported, such as XueShuanTong injection ([@B58]) and QianCao NaoMaiTong mixture ([@B72]).

Most, such as Cerebralcare Granule^®^ ([@B108]), DanHong injection ([@B141]; [@B63]), and AnGong NiuHuang wan ([@B121]; [@B113]), can inhibit ischemia-evoked neuronal apoptosis by regulating bcl-2 family members. As a prescription commonly used in Tibetan medicine to treat ischemic sequelae, our research group proved that the anti-cerebral ischemia effect of ErShiWei ChenXiang pills may be related to its regulation of Bcl-2 family, inhibition of apoptosis, and increase of energy supply ([@B45]). While regulating Bcl-2 family members, AnNao tablets ([@B164]) and YiQi FuMai powder injection ([@B20]; [@B142]) may also be involved in inflammation and mitochondrial autophagy to maintain mitochondrial MMP and energy production. In addition, both TongXinLuo\'s regulation of AKT/ERK signaling ([@B152]; [@B27]) and XingNaoJing injection\'s regulation of the PI3K-AKT pathway ([@B160]) ultimately contributed to the regulation of Bcl-2 and the inhibition of ischemic neuron apoptosis. In addition to the Bcl-2 family, it was reported that Zhenlong Xingnao capsule ([@B134]) and NaoLuoTong capsule ([@B7]) could also be through the regulation of NF-кB to confine ischemia induced inflammatory cascade process. Of course, multiple mechanisms of drugs have also been reported against ischemic neuron apoptosis. QingKaiLing injection could simultaneously inhibit oxidative stress, activation of NLRP3 inflamosome and AMPK signaling pathway, and thus inhibiting neuronal apoptosis ([@B26]). PienTzeHuang capsule suppressed the inflammatory and apoptotic cascade of ischemia by regulating AKT/GSK-3β and the Bcl-2 family ([@B159]). As a fatal blow to the body, disregardful ischemic stroke induced hypoimmunity was also one of the main culprits of exacerbating stroke. Noteworthy, XueSaiTong ([@B65]) and Danggui-Jakyak-San ([@B51]) may mediate inflammatory responses by regulating STAT3 signaling pathway, and enhance immune function of the body, which were helpful to reduce symptoms of brain injury after ischemia. The above officially certified drugs' information and specific mechanisms of action are shown in [**Supplementary Table 1**](#SM1){ref-type="supplementary-material"}, and [**Tables 1**](#T1){ref-type="table"} and [**2**](#T2){ref-type="table"}. Through in-depth comparative analysis, we found that although the above drugs prevailing in the market have good clinical efficacy, most of their active ingredients, *in vivo* pharmacokinetic parameters, and potential targeted organ toxicity have not been well evaluated. Importantly, the further regulation of apoptosis still has good research value and prospect. Although there is no direct evidence that they regulate MPTP to inhibit ischemic neuron apoptosis, their effect on members of the Bcl-2 family makes MPTP a potential target for anti-stroke drugs.

###### 

The *in vivo* mechanism underlying the inhibition of MPTP opening-induced neuronal apoptosis by authorized drugs in the treatment of ischemic stroke.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Agents                        Objects             Gender   Weight (g)      Animal model             Dose                                Time periods                                                   Mechanisms                                                                                                                                          References
  ----------------------------- ------------------- -------- --------------- ------------------------ ----------------------------------- -------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------- ------------
  XueShuanTong injection        SD                  Both     270--320        MCAO (2 h)/R (46 h)      25 mg/kg, i.p.                      Pretreatment for 5 min and 12/24/36 h after MCAO               Caspase-1/3↓, TUNEL-positive neurons↓                                                                                                               [@B58]

  Cerebralcare granule          Mongolian gerbils   Male     65--90          MCAO (0.5 h)/R (5 d)     0.4 and 0.8 g/kg, i.g.              3 h after the reperfusion, 5 d, q.d.                           Bcl-2↑; leukocyte adhesion↓, fluorescence intensity of DHR↓, albumin leakage↓, Caspase-3↓, Bax↓, TUNEL-positive neurons↓                            [@B108]

  AnGong NiuHuang wan.          SD                  Male     250--280        MCAO (1.5 h)/R (24 h)    0.065, 0.125, and 0.25 g/kg, i.g.   Pretreatment 3 d, q.d., and 1 d, q.d. after reperfusion        Bcl-2↑; Bax↓, Caspase-3↓, TUNEL-positive neurons↓                                                                                                   [@B121]

                                SD                  Male     260--280        MCAO (2 h)/R (22 h)      257 mg/kg, i.g.                     Single dose before reperfusion                                 Bcl-2↑, ZO-1↑, claudin-5↑, eNOS↑; Bax↓, p47~phox~↓, iNOS↓, 3-NT↓, MMP-2↓, MMP-9↓, iNOS↓                                                             [@B113]

  QingKaiLing injection         KM/C57BL/6          Male     25--28/25--30   MCAO (1.5 h)/R (28 h)    3 ml/kg, i.v.                       4 h after reperfusion, and once every 12 h, three times        Procaspase-12↑; Caspase-3↓, p-eIF2α↓, ROS↓, Ca^2+^↓, TUNEL-positive neurons↓                                                                        [@B26]

  DangGui Jakyak san            SD                  Male     ------          pMCAO (28 d)             50, 100, and 200 mg/kg, i.g.        24 h after surgery, 28 d, q.d.                                 STAT3↑, Pim-1↑, GSH↑, SOD↑, CAT↑; MDA↓, Caspase-3↓, PARP↓, NT↓, 4-HNE↓                                                                              [@B51]

  YiQi FuMai powder injection   C57BL/6J            Male     18--22          pMCAO (24 h)             1.342 g/kg, i.p.                    Single dose after pMCAO onset                                  cerebral blood flow↑, Bcl-2↑; Caspase-12↓, GRP78↓, CHOP↓, ATF-4/6↓, p-eIF2*α*/eIF2*α*↓, XBP-1↓                                                      [@B20]

                                SD                  Male     280--300        tMCAO (1.5 h)/R (24 h)   0.957 g/kg, i.p.                    Single dose after tMCAO onset                                  Bcl-2↑, cytosolic Drp1↑; Bax↓, cleaved Caspase-9↓, mtDrp1↓, total p-Drp1 and Drp1↓                                                                  [@B142]

  TongXinLuo                    SD                  Male     200--220        MCAO (1.5 h)/R (24 h)    0.4, 0.8, and 1.6 g/kg, i.g.        Pretreatment for 3 d, b.i.d., and after MCAO for 1 d, b.i.d.   p-PTEN/PTEN↑, p-PDK1/PDK1↑, p-AKT/AKT↑, p-Bad/Bad↑, p-c-Raf/c-Raf↑; cleaved Caspase-3↓, TUNEL-positive neurons↓                                     [@B152]

                                SD                  Male     240--270        MCAO (1.5 h)/R (14 d)    0.1 g/kg, i.g.                      Pretreatment for 5 d and 14 d after MCAO, q.d.                 Connexin 43↓, Calpain II↓, Bax↓, cleaved Caspase-3↓, TUNEL-positive neurons↓                                                                        [@B27]

  QianCao NaoMaiTong mixture    SD                           180--200        MCAO (2 h)/R             2.7, 5.4, and 10.8 ml/kg            Pretreatment for 28 d                                          Bcl-2/Bax↑, SOD↑, CAT↑, BDNF↑, ICAM-1↑, NGF↑, MDA↓, IL-6↓                                                                                           [@B72]

  DanHong injection             SD                  Male     250--280        MCAO (1 h)/R (24 h)      4 ml/kg, i.p.                       4 h after MCAO                                                 claudin-5↑, occludin↑, ZO-1↑, Bcl-2↑; Bax↓, Caspase-3↓, MMP-9↓, PAI-1↓, P-selectin↓                                                                 [@B63]

  XingNaoJing injection         SD                  Male     250--280        MCAO (2 h)/R (24 h)      5, 10, and 15 ml/kg, i.p.           24 h after reperfusion                                         Bcl~2~/Bax↑, p-PI3K/PI3K↑, p-AKT (308 and 473)/AKT↑, p-eNOS/ eNOS↑, NO↑, p-PI3K/AKT↑                                                                [@B160]

  PienTzeHuang capsule          SD                  Male     240--260        MCAO (1.5 h)/R (24 h)    180 mg/kg, i.g.                     Pretreatment 4 d before\                                       NeuN↑, mtCyto-c↑, Bcl-xl↑, p-AKT↑, p-GSK-3β↑; IL-1β↓, IL-6↓, TNF-α↓, cytosolic Cyto-c↓, Bax↓, p53↓, cleaved Caspase-3/9↓, TUNEL-positive neurons↓   [@B159]
                                                                                                                                          MCAO                                                                                                                                                                                                               

  XueSaiTong                    C57BL/6             Male     20--25          MCAO (45 min)/R (14 d)   15 µg/g, i.v.                       Immediately after reperfusion, 14 d, q.d.                      arginase-1↑, CD206↑, CD206/Iba-1↑, IL-10↑, TGF-β1↑; IL-1β↓, p-STAT3/STAT3↓, CD16↓, CD16/Iba-1↓, iNOS↓, TUNEL-positive neurons↓                      [@B65]

  NaoLuoTong capsule            Wistar              Male     250--280        MCAO (2 h)/R (22 h)      75, 150, and 300 mg/kg, i.g.        Pretreatment for 7 d, q.d.                                     Bcl-2↑, NGF↑; TNF-α↓, IL-1β↓, IL-6↓, Bax↓, Caspase-3↓, ICAM-1↓, NF-κBp65↓                                                                           [@B7]

  ZhenLong XingNao capsule      Wistar              Male     200--250        MCAO (1.5 h)/R (24 h)    125 and 250 mg/kg, i.g.             Pretreatment 14 d, q.d.                                        T-AOC↑, T-SOD↑, Bcl-2↑, Bcl-2/Bax↑; Caspase-3↓, NF-кB↓, p38↓, Bax↓, MDA↓, GABA↓, Glu↓, Tau↓                                                         [@B134]

  ErShiWei ChenXiang pills      SD                  Male     260--300        MCAO (2 h)/R (24h)       1.33 and 2.00 g/kg, i.g.            Pretreatment 14 d, q.d.                                        Bcl-2↑, CaMK II↑; Bax↓, cleaved Caspase-3↓, Cyto-c↓, ATF4↓, c-Jun↓, TUNEL-positive neurons↓                                                         [@B45]

  AnNao tablets                 SD                  Male     250--270        MCAO (2 h)/R (7 d)       300, 600, and 1,200 mg/kg, i.g.     1 h after reperfusion, 1 d or 7 d, q.d.                        Drp1↑, OPA1↑, PINK1↑, Parkin↑, Bcl-2↑, Bcl-2/Bax↑; Bax↓                                                                                             [@B164]
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

↑, upgrade; ↓, downgrade.

###### 

The *in vitro* mechanism underlying the inhibition of MPTP opening-induced neuronal apoptosis by authorized drugs in the treatment of ischemic stroke.

  Agents                        Cell lines                             Model                                                                       Dose                                   Time periods                                                                             Mechanisms                                                                                                                                                                                                               References
  ----------------------------- -------------------------------------- --------------------------------------------------------------------------- -------------------------------------- ---------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------
  TongLuo JiuNao injection      BMECs of SD rats                       OGD (95% N~2~ and 5% CO~2~ 6 h)/R (74% N~2~, 21% O~2~, and 5% CO~2~, 6 h)   2 μl/ml                                Before OGD, the neurons were incubated 6 h in drug treatment and then equilibrated OGD   VEGF↑, MMP↑; LDH↓, Ca^2+^↓, cytosolic Cyto-c↓, NMDAR1↓, PAF↓                                                                                                                                                             [@B60]
  QianCao NaoMaiTong mixture    SH-SY5Y                                OGD (N~2~, 1 h)/R (24 h)                                                    0.5, 1, 5, 10, 50, 100 and 200 mg/ml   Pretreatment for 2 h and during reperfusion period                                       Caspase-3/8↓, neuronal apoptosis under flow cytometry↓                                                                                                                                                                   [@B72]
  YiQi FuMai powder injection   PC12                                   OGD (5% CO~2~, 94% N~2~, and 1% O~2,~ 12 h)                                 100, 200, and 400 μg/ml                during OGD period                                                                        Bcl-2↑; neuronal apoptosis under flow cytometry↓, Caspase-3↓, cleaved Caspase-3↓, Caspase-12↓, CHOP↓, GRP78↓, ATF-4/6↓, p-eIF2*α*/eIF2*α*↓, XBP-1↓, Hoechst 33342 positive neurons↓                                      [@B20]
                                PCN of embryonic, 16--18-d SD rats     100 μM H~2~O~2~ for 12 h                                                    100, 200, and 400 μg/ml                6 h before and during H~2~O~2~ treatment                                                 ATP↑, MMP↑; Bcl-2↑, Bcl-xl↑, cytosolic Drp1↑, cytosolic PKCδ↑; Bax↓, Bak↓, Caspase-3↓, cleaved Caspase-3↓, mtROS↓, PKCδ↓, neuronal apoptosis under flow cytometry↓, intracellular ROS↓, p-Drp1/Drp1↓, mtDrp1↓, mtPKCδ↓   [@B142]
  DanHong injection             PCN of embryonic, 14-d C57 BL/6 mice   OGD (95% N~2~ and 5% CO~2~, 6 h)                                            0.01, 0.03, 0.1, 0.3, and 1 μl/ml      During OGD period                                                                        LDH↓, ROS↓, Ca^2+^↓, neuronal apoptosis under flow cytometry↓                                                                                                                                                            [@B141]
  XingNaoJing injection         HBMECs                                 OGD (5% CO~2~, 85% N~2~, and 10% H~2,~ 3 h)/R (24 h)                        1.5 and 2.5 *μ*l/ml                    Pretreatment for 1 h and during reperfusion period                                       p-eNOS/eNOS↑, MMP↑, NO↑; cleaved Caspase-3/Caspase-3↓, neuronal apoptosis under flow cytometry↓                                                                                                                          [@B160]

↑, upgrade; ↓, downgrade.

Prescription and Molecular Mechanisms in Regulating MPTP Openness of Ischemic Stroke {#s2_2}
------------------------------------------------------------------------------------

Clinical experience has proved that TCM has excellent efficacy in treating stroke, which can be seen in *Huangdi Neijing*. But at bottom it is the cold, hot, warm, cool, and other characteristics of drugs to balance the imbalance of Yin and Yang in the body under the condition of disease. In ischemic stroke, a variety of exogenous pathogens and dysfunction of the viscera can lead to poor blood flow or blood stasis, resulting in cerebral ischemia or hypoxia ([@B45]). Therefore, the clinic mainly focuses on promoting blood circulation to remove stasis, replenishing Qi to nourish blood, and nursing viscera. Extensive clinical and *in vivo* and *in vitro* studies have confirmed that prescriptions SiJunZi decoction ([@B147]), ShengMai san ([@B59]), and YangYin TongNao granules ([@B131]) have a significant effect on ischemic stroke. Of course, the regulation of oxidative stress and inflammatory response are also common mechanisms of prescription in the treatment of ischemic brain injury. The antioxidant and anti-inflammatory activities of ShengNaoKang decoction ([@B24]) could contribute to the inhibition of apoptosis and the alleviation of ischemic brain injury. Other studies have reported that HuangLian JieDu decoction (HJD) could inhibit ischemic neuron apoptosis by regulating PI3K/AKT and HIF-1α/VEGF ([@B156]). Further metabolomics ([@B180]) and systemic pharmacology ([@B127]) studies have revealed that its anti-ischemic protective effect may also involve the Bcl-2 family such as Bak. Regulating vascular function and increasing cerebral blood flow supply is another effective strategy for stroke treatment. Abundant evidence demonstrated that BuYang HuanWu decoction (BHD) could increase cerebral blood by regulating HIF-1α/VEGF-related signaling pathways ([@B25]). Improving the mitochondrial ATP supply has also been shown to be an effective treatment for stroke. BHD has been reported to improve ischemic brain injury by reducing glutamate-mediated excitatory amino acid toxicity, resulting in enhanced ATP supply and weakened apoptosis ([@B119]). At the same time, the improved synaptic ultrastructure by BHD also contributed to the recovery of cerebral ischemia sequelae ([@B87]). Similarly, ShenGui SanSheng san could also improve the efficiency of citric acid cycle to improve the brain energy deficit after ischemia ([@B74]). Interestingly, as a cell-sensing oxygen sensor, most studies have also reported evidence of other TCM prescriptions regulating HIF-1α to inhibit apoptosis and inflammation in treatment of stroke, such as XueFu ZhuYu decoction ([@B57]) and TaoHong SiWu decoction ([@B151]). Members of the Bcl-2 family are also potential targets for prescription inhibition of apoptosis to improve ischemic brain injury. XiaoXuMing decoction ([@B55]), ShuanTongLing ([@B81]), and GuaLou Guizhi decoction ([@B157]) all have the potential to regulate the Bcl-2 family and inhibit caspase-dependent mitochondrial apoptosis, which has a similar mechanism to that of MuXiang You fang ([@B169]) reported in our previous study. In addition to the Bcl-2 family, DiHuang YinZi ([@B46]) and DiDang tang ([@B47]) could also inhibit the generation of Ca^2+^ and improve MMP to inhibit the apoptosis of ischemic neurons by regulating the ERK signaling pathway. It has also been reported that HouShiHei san ([@B21]) could regulate PI3K/Akt signaling to inhibit the apoptosis of ischemic neurons. The specific mechanisms *in vivo* and *in vitro* of the above prescriptions are shown in [**Table 3**](#T3){ref-type="table"}.

###### 

The *in vivo* and *in vitro* mechanism underlying the inhibition of MPTP opening-induced neuronal apoptosis by TCM prescriptions in the treatment of ischemic stroke.

  *In vivo* study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  ------------------------- ------------ -------------------------------------------------- ------------------------ ------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------
  DiHuang YinZi             Wistar       Both                                               320--350                 MCAO (1 h)/R (10 d)                                    6 and 12 g/kg, i.g.                                                                                                                                                       30 min after MCAO, 10 d, q.d.                          synaptophysin↑, ERK↑; LDH↓, TUNEL-positive neurons↓                                                                                                                                          [@B46]
  XueFu ZhuYu decoction     Wistar       Male                                               250--300                 MCAO (1 h)/R (24 h)                                    1.5 and 3.0 g/kg, i.g.                                                                                                                                                    Pretreatment for 14 d, q.d.                            cleaved Caspase-3↓, HIF-1α↓, TNF-α↓, iNOS↓                                                                                                                                                   [@B57]
  BuYang HuanWu decoction   ICR          Male                                               17--22                   MCAO (30 min)/R (14 d)                                 0.5 and 1.0 g/kg, i.g.                                                                                                                                                    2 h after reperfusion, 14 d, b.i.d.                    glucose metabolism↑, BrdU↑; ROS↓, TUNEL-positive neurons↓, CD11b↓                                                                                                                            [@B119]
  ShengNaoKang decoction    SD           Male                                               280--320                 MCAO (2 h)/R (24 h)                                    0.7, 1.4, and 2.8 g/kg, i.g.                                                                                                                                              Pretreatment for 6 d and 1 d after reperfusion, q.d.   SOD↑; GSH-Px↑, Caspase-3↓, MDA↓, iNOS↓, TNOS↓                                                                                                                                                [@B24]
  TaoHong SiWu decoction    Wistar       Male                                               250--300                 MCAO (1 h)/R (24 h)                                    0.7 g/kg, i.g.                                                                                                                                                            Pretreatment for 14 d, q.d.                            cleaved Caspase-3↓, HIF-1α↓, iNOS↓, TNF-α↓                                                                                                                                                   [@B151]
  HuangLian JieDu tang      SD           Male                                               300--350                 MCAO (2 h)/R (72 h)                                    2.7 g/kg, i.g.                                                                                                                                                            Single dose and pretreatment for 24 h                  p-PI3K/PI3K↑, p-AKT/AKT↑, HIF-1α↑, EPO↑, VEGF↑, BrdU↑; LDH↓, TUNEL-positive neurons↓                                                                                                         [@B156]
  XiaoXuMing decoction      SD           Male                                               250--280                 MCAO (1.5 H)/R (24 h)                                  60 g/kg, i.g.                                                                                                                                                             Pretreatment for 3 d, t.i.d.                           mtBcl-2↑, mtCyto-c↑, cytoplasmic Bax↑, cytoplasmic c-IAP1↑; mtbroken cristae↓, cleaved Caspase-3/9↓, p53↓, mtp53↓, mtBax↓, cytoplasmic Smac↓, cytoplasmic Cyto-c↓, TUNEL-positive neurons↓   [@B55]
  GuaLou Guizhi decoction   SD           Male                                               280--300                 MCAO (2 h)/R (7 d)                                     14.4 g/kg, i.g.                                                                                                                                                           Posttreatment for 7 d, q.d.                            NeuN↑, MAP-2↑, Bcl-2↑; GFAP↓, Bax↓, TUNEL-positive neurons↓                                                                                                                                  [@B157]
  MuXiang You fang          SD           Male                                               260--300                 MCAO (2 h)/R (48 h)                                    58, 116, and 232 mg/kg, i.g.                                                                                                                                              Posttreatment for 3 d, q.d.                            Bcl-2↑, Bcl-2/Bax↑; Bax↓, Cyto-c↓, Caspase-3/7/9↓                                                                                                                                            [@B169]
  ShuanTongLing             SD           Male                                               250--280                 MCAO (1.5 h)/R (24 h)                                  5.7 and 17.2 ml/kg, i.g.                                                                                                                                                  Pretreatment for 7 d, q.d.                             SIRT1↑, Bcl-2↑; TNF-α↓, IL-1β↓, Ac-p53↓, Bax↓                                                                                                                                                [@B81]
  *In vivo* study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  Agents                    Cell lines   Model                                              Dose                     Time periods                                           Mechanisms                                                                                                                                                                                                                                                                                                                                                                                                                    References
  DiDang tang               PC12         OGD (95% N~2~ and 5% CO~2~, 0.5--2.5 or 2--10 h)   12.5, 25, and 50 mg/ml   After the OGD induced PC12 cell model for 24 or 48 h   Bcl-2/Bax↑; Ca^2+^↓, MMP↓, GRP78↓, p-IRE1/IRE1↓, p-PERK/PERK↓, p-eIF2*α*/eIF2*α*↓, p-Bad/Bad↓, ATF-6↓, Cyto-c↓, cleaved PARP↓, neuronal apoptosis under flow cytometry↓   [@B47]                                                                                                                                                                                                                                              

↑, upgrade; ↓, downgrade.

The above evidence indicates that most TCM prescriptions could more or less improve mitochondrial morphology and respiratory function by inhibiting neuronal Ca^2+^ overload through anti-oxidative stress and anti-inflammatory. Meanwhile, we note that most of them also regulates many members of the Bcl-2 family to inhibit ischemic neuron apoptosis. We, therefore, see the potential of drugs to indirectly inhibit MPTP opening to improve ischemic neuron apoptosis. Nevertheless, the unclear drug distribution of target organs and the intricate network of interactive targets should still drive us to further study.

Herbal Extracts and Molecular Mechanisms in Regulating MPTP Openness of Ischemic Stroke {#s2_3}
---------------------------------------------------------------------------------------

The overall concept of TCM and the characteristics of treatment based on syndrome differentiation of ethnic medicine determine that prescriptions from diversified drug sources are mainly used in the treatment of diseases. The purpose is to comprehensively consider the functions of viscera to exorcize evil spirits while strengthening the body, and finally cure diseases. However, in addition to conventional prescriptions mentioned above, people have also discovered that the individual application of certain herbs also has the potential to treat diseases. Based on recent literature reports, most of them exhibit outstanding antioxidant effects, such as methanol extract of *Artemisia absinthium* ([@B13]) and *Colebrookea oppositifolia* Smith ([@B116]). As the most sensitive hippocampal neuron to ischemic invasion, studies have shown that *Moringa oleifera* seed extract could promote hippocampal nerve regeneration, enhance synaptic plasticity and cholinergic function to treat ischemic stroke ([@B154]). More interestingly, *Gynostemma pentaphyllum* extract could protect OGD/R-induced rats isolated hippocampal slices damage by inhibiting neuronal Ca^2+^ overload and mitochondrial oxidative stress-induced MPTP opening ([@B97]), which may help to inhibit the MPTP opening-activated mitochondrial apoptotic cascade event. At the same time, herbs could regulate the expression level of anti-apoptotic and pro-apoptotic proteins of Bcl-2 family and inhibit mitochondrial apoptosis in the treatment of hypoxia brain injury. The specific *in vivo* and *in vitro* mechanisms of reported herbs for ischemic stroke treatment by inhibiting mitochondrial MPTP opening-induced neuronal apoptosis are shown in [**Tables 4**](#T4){ref-type="table"} and [**5**](#T5){ref-type="table"}. [**Figure 2**](#f2){ref-type="fig"} shows pictures of 16 representative herbs. It is world-renowned that superior immune enhancement of plant polysaccharides could prevent and cure many diseases. Previous investigations reported the anti-ischemic effects of *Ganoderma lucidum* polysaccharides (GLP) ([@B176]), *Lycium barbarum* polysaccharide (LBP) ([@B122]; [@B171]), *Panax notoginseng* polysaccharides (PNP) ([@B35]), and *Cistanche deserticola* polysaccharides (CDP) ([@B68]) were associated with anti-oxidant activity and the regulation of Bcl-2 family members to maintain mitochondrial function and morphology. Furthermore, *Achyranthes bidentata* polypeptides (ABP) ([@B101]), astragalosides ([@B29]), and phenolic acid extracts derived from *Sargentodoxa cuneata* ([@B7]) and *Salvia miltiorrhiza* ([@B44]; [@B146]; [@B135]) also have potential anti-ischemic stroke effects. In conclusion, although the clinical treatment of ischemic stroke with a single herb is rare, a large number of definitive *in vitro* and *in vivo* and clinical reports are sufficient to support further studies. However, the mechanism of some herbs with better efficacy proved by experiments is still in the preliminary stage, and the ischemic brain protection mechanism of anti-neuronal apoptosis is worthy of further exploration. More promisingly, some ethnic herbs for stroke prevention, such as Tibetan medicine saffron ([@B86]) and Mongolian medicine Eerdun Wurile ([@B40]), have also been gradually reported in recent years. In the early stage, our research group also revealed that the anti-hypoxia brain protection effect of the Tibetan medicine *Rhodiola crenulata* was related to the regulation of the HIF-1α/microRNA 210/ISCU1/2(COX10) signal pathway to improve mitochondrial energy metabolism, inhibit oxidative stress and mitochondrial apoptosis ([@B128]). Although the medication law of ethnic medicine for prevention and treatment of ischemic stroke is bound to limit the scope of effective single herbal medicine. But optimistically taking the long view, such a gradual herbal medicine research model should be warranted.

###### 

The *in vivo* mechanism underlying the inhibition of MPTP opening-induced neuronal apoptosis by herbal medicine in the treatment of ischemic stroke.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Agents                                Objects        Gender   Weight (g)   Animal model                  Dose                           Time periods                                           Mechanisms                                                                                                                                                                                                                          References
  ------------------------------------- -------------- -------- ------------ ----------------------------- ------------------------------ ------------------------------------------------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------
  Curcuma oil                           SD             Male     200--225     MCAO (1 h)/R (24 h)           250 mg/kg, i.p.                Single dose and pretreatment for 0.5 h                 Bcl-2↑, MMP↑; MPO↓, nitrite↓, nitrate↓, iNOS↓, nNOS↓, e NOS↓, peroxynitrite↓, ROS↓, Ca^2+^↓, Cyto-c↓, p53↓, cleaved Caspase-3, Bax↓, TUNEL-positive neurons↓, neuronal apoptosis under flow cytometry↓                              [@B34]

  Hawthorn extract                      SD             Male     300--320     MCAO (1.25 h)/R (3 or 24 h)   100 mg/kg, i.g.                Pretreatment for 15 d, q.d.                            Bcl-xL↑, Foxp3↑, pSTAT-3/STAT-3↑; IL-10↑; MPO↓, TNF-α↓, IL-6↓, IL-1β↓, ICAM-1↓, CD3^+^ & CD8^+^ positive cells↓, TUNEL-positive neurons↓                                                                                            [@B37]

  *Rosa laevigata* Michx                SD             Male     250--300     MCAO (2 h)/R (24 h)           50, 100, and 200 mg/kg, i.g.   Pretreatment for 7 d, q.d.                             Bcl-2↑, SOD↑, GSH↑, MMP↑; MDA↓, T-NOS↓, NO↓, iNOS↓, MMP-9↓, p53↓, Apaf1↓,Fas↓, Fasl↓, Bax↓, Bid↓, Cyto-c↓, cleaved Caspases-3/8/9↓, NF-κB↓, COX-2↓, TNF-α↓, IL-1β↓, IL-4↓, IL-6↓, p-JNK↓, p-ERK↓, p-p38↓, TUNEL-positive neurons↓   [@B155]

  PNP                                   Wistar         Male     250--300     MCAO (2 h)/R (22 h)           50, 100, and 200 mg/kg, i.g.   Pretreatment for 7 d, q.d.                             Bcl-2/Bax↑; cleaved Caspase-3↓, TUNEL-positive neurons↓                                                                                                                                                                             [@B35]

  LBP                                   ICR            Male     20--25       MCAO (2 h)/R (24 h)           10, 20, and 40 mg/kg, i.g.     Pretreatment for 7 d, q.d.                             Bcl-2↑; Bax↓, Cyto-c↓, Caspases-3/9↓, cleaved PARP-1↓, TUNEL-positive neurons↓                                                                                                                                                      [@B122]

  Rhizoma Pinelliae Pedatisectae        SD             Male     250--300     MCAO (2 h)/R (24 h)           5, 10, and 20 mg/kg, i.g.      Pretreatment for 7 d, b.i.d.                           SOD↑, Bcl-2↑; Bax↓, MDA↓, TNF-α↓, IL-1 β↓, TUNEL-positive neurons↓                                                                                                                                                                  [@B150]

  *Clinacanthus nutans* Lindau          Long-Evans     Male     ------       MCAO (0.5 h)/R (24 h)         10--60 pg, icv;\               Single dose and 30 min after MCAO;\                    PPAR-γ↑, C/EBPβ↑, 14-3-3ϵ↑, p-Bad↑, Bad↑, Bcl-2↑; cleaved Caspase-3↓, PARP↓                                                                                                                                                         [@B138]
                                                                                                           24 mg/kg, i.p.                 pretreatment for 1 h or posttreatment for 3--24 h                                                                                                                                                                                                                                          

  Spatholobi Caulis extract             SD             Male     240--260     MCAO (0.75 h)/R (7 d)         100 and 200 mg/kg, i.g.        Pretreatment for 3 d and posttreatment for 7 d, q.d.   BDNF↑, β-III-tubulin↑, ROS↓, GFAP↓, cleaved PARP↓, cleaved Caspases-3↓, p-p38↓, p-JNK↓, TUNEL-positive neurons↓                                                                                                                     [@B90]

  Radix Scrophulariae aqueous extract   KunMing mice   Male     18--22       MCAO (2 h)/R (22 h)           2.4 g/kg, i.g.                 Pretreatment for 7 d; q.d.                             Bcl-2↑, SOD↑, MDA↓, NO↓, Bax↓, p-ERK1/2↓, p-P38↓                                                                                                                                                                                    [@B82]
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

↑, upgrade; ↓, downgrade.

###### 

The *in vitro* mechanism underlying the inhibition of MPTP opening-induced neuronal apoptosis by herbal medicine in the treatment of ischemic stroke.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Agents                                 Cell lines                              Model                                                                        Dose                                  Time periods                                                  Mechanisms                                                                                                                                                                                       References
  -------------------------------------- --------------------------------------- ---------------------------------------------------------------------------- ------------------------------------- ------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------
  ABP                                    PHN of embryonic, 18-d SD rats          OGD (NMDA insult, 0.5 h)/R (24 h)                                            1 µg/ml                               Pretreatment for 12 h and during OGD/R period                 MMP↑; Bax↓, Caspase-3↓, ROS↓                                                                                                                                                                     [@B101]

  GLP                                    PCN of neonatal SD rats (\<24 h)        OGD (5% CO~2~ and 95% N~2,~ 2 h)/R (24 h)                                    0.1, 1.0, and 10.0 μg/ml              Pretreatment for 0.5 h and during OGD/R period                Bcl-2↑; cleaved Caspases-3/8/9↓, Bax↓                                                                                                                                                            [@B176]

  Astragalosides                         PC12                                    OGD (5% CO~2~ and 95% N~2,~ 5 h)/R (24 h)                                    1, 100, and 200 g/ml                  During reperfusion period                                     MMP↑, p-p38/p38↑,; fragmented DNA↓, LDH↓, Caspase-3/9/12↓, cleaved Caspases-3/9↓, ROS↓, LC3--11↓, Bip↓, neuronal apoptosis under flow cytometry↓,                                                [@B29]

  *Clinacanthus nutans* Lindau           PCN of embryonic, 15.5-d Balb/c mouse   OGD (0.02--0.1% O~2~, 5% CO~2~, 10% H~2~, and 85% N~2~, 0.5 h)/R (4--24 h)   6.25 μg/ml                            Pretreatment for 1 h and during OGD/R period                  14-3-3ϵ↑, C/EBPβ↑, PPAR-γ↑, p-Bad↑, Bcl-2↑, MMP↑; cleaved Caspase-3↓, PARP-1↓                                                                                                                    [@B138]

  LBP                                    PHN of neonatal SD rats (\<24 h)        OGD (5% CO~2~ and 95% N~2,~ 2 h)/R (24 h)                                    10, 20, and 40 mg/L                   During reperfusion period                                     MMP↑, IκB-α↑, LDH↓, ROS↓, Ca^2^ ^+^↓, IL-6↓, TLR4↓, NF-κB↓, Hoechst 33342 positive neurons↓, TUNEL-positive cells↓                                                                               [@B171]

  Spatholobi Caulis\                     SH-SY5Y                                 A-24 h etoposide insult                                                      25 and 50 μg/ml                       Pretreatment for 6 h and co-culture with etoposide for 24 h   MMP↑; cleaved PARP↓, p-p53↓, cleaved Caspase-3↓, Caspase-3/7↓, p-JNK/JNK↓, p-p38 /p38↓, TUNEL-positive neurons↓, neuronal apoptosis under flow cytometry↓                                        [@B90]
  extract                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  Radix Scrophulariae aqueous extract    PC12                                    OGD (5% CO~2~ and 95% N~2,~ 2 h)/R (24 h)                                    6.25, 12.50, 25.00, and 50.00 µg/ml   Pretreatment for 24 h                                         Bcl-2↑, SOD↑, GSH-Px↑, CAT↑, MMP↑; LDH↓, MDA↓, NO↓, Bax↓                                                                                                                                         [@B82]

  CDP                                    PC12                                    OGD (5% CO~2~ and 95% N~2~, 4 h)/R (24 h)                                    0.05, 0.50, and 5.00 μg/ml            During reperfusion period                                     CAT↑, GSH-Px↑, T-AOC↑, MMP↑, DJ-1↑; ROS↓, LDH↓, MDA↓, Ca^2+^↓, neuronal apoptosis under flow cytometry↓, Hoechst33342 positive neurons↓                                                          [@B68]

  *Scutellaria barbata* D. Don extract   PC12                                    OGD (1% O~2,~ 5% CO~2~, and 94% N~2~, 6 h)/R (18 h)                          0.1--0.8 mg/ml                        Pretreatment for 12--48 h                                     p-PI3K/ PI3K↑, p-AKT/AKT↑, p-PI3K↑, p-AKT↑, Nrf2↑, SOD↑, GSH↑, MMP↑, Ki67 positive cells↑,Cycin D1↑, Cyclin E↑; MDA↓, Bax↓, cleaved Caspase-3↓, Bid↓, neuronal apoptosis under flow cytometry↓   [@B130]

  *Aglaia odorata* Lour. extract         PC12                                    OGD (5% CO~2~ and 95% N~2,~ 4 h)/R (24 h)                                    5, 10, and 50 ng/ml                   During OGD/R period                                           MMP↑, Caspase-3↑, PARP↑, Bcl-2↑; LDH↓, cleaved PARP↓, cleaved Caspase-3/9↓, Bax↓, p53↓, Puma↓, mtROS↓, AO/EB and Hoechst 33258 positive neurons↓                                                 [@B132]
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

↑, upgrade; ↓, downgrade.

![Representative herbal images that may inhibit ischemic neuron apoptosis by regulating MPTP. Sixteen herbs are shown here.](fphar-11-00352-g002){#f2}

Monomers and Molecular Mechanisms in Regulating MPTP Openness of Ischemic Stroke {#s2_4}
--------------------------------------------------------------------------------

As research continues, massive active ingredients for treating stroke have been identified from herbal medicines. According to literature reports, we summarized 29 monomer compounds that may target to inhibit mitochondrial MPTP overopening-induced neuronal apoptosis, including alkaloids, flavonoids, terpenoids, and phenolic acids. [**Figure 3**](#f3){ref-type="fig"} shows the structure information of these potential compounds. [**Tables 6**](#T6){ref-type="table"} and [**7**](#T7){ref-type="table"} list the specific brain protective mechanisms of monomer compounds against ischemia-induced neuronal apoptosis. Notably, some of these compounds have been shown to regulate MPTP to improve ischemic stroke. The anti-oxidant and anti-inflammatory effects of hydroxy safflor yellow A (HSYA) and carboxyatractyloside could help to inhibit ischemia-induced MPTP opening and play a protective role against cerebral ischemia ([@B95]). The anti-hypoxic effect of kaempferol was related to inhibition of mitochondrial fission, maintenance of mitochondrial integrity and function, and therefore repressing MPTP opening-induced apoptosis ([@B137]). *In vivo* and *in vitro* experiments showed that the protective effect of gallic acid (GA) on cerebral ischemia against apoptosis might be related to inhibition of oxidative stress response, Ca^2+^ and ROS overproduction-evoked MPTP opening, and the transfer of mitochondrial Cyto-c to the cytoplasm, and thus increasing mitochondrial ATP supply and MMP ([@B109]). The authors further illuminated that GA could inhibit MPTP-induced apoptosis by regulating ERK-CypD axis, which may make GA a natural MPTP opening inhibitor for treating ischemic stroke ([@B110]). Earlier studies have reported that the anti-oxidative stress and apoptotic properties of trans resveratrol ([@B2]) and resveratrol ([@B84]) may lead to a protective effect against ischemia. Subsequently, studies confirmed that OGD/R induced bEND3 cerebrovascular endothelial cell edema was associated with monocyte chemoattractant protein and intracellular Ca^2+^ overload, while resveratrol could maintain mitochondrial MMP by inhibiting ROS and elevated Ca^2+^ ions, thus improving hypoxic brain edema ([@B89]). Excitingly, recent study has further demonstrated that the anti-anoxic brain protection of preadministrated resveratrol may be related to consolidating mitochondrial tolerance to anoxia and increasing VDAC level and energy synthesis ([@B50]). However, on the contrary, picroside II could interdict release of pro-apoptotic factor Endo G into the nucleus driven by MPTP opening, ROS production and VDAC1 protein expression ([@B64]). Therefore, it is worth further focus on VDAC, one of the main components of MPTP, as an interesting target for stroke treatment.

![The structural information of underlying compounds for regulation of MPTP opening to inhibit apoptosis in ischemic neurons. The structural formulae of 29 monomer compounds are shown in the figure.](fphar-11-00352-g003){#f3}

###### 

The *in vivo* mechanism underlying the inhibition of MPTP opening-induced neuronal apoptosis by monomeric compounds in the treatment of ischemic stroke.

  Agents             Objects    Gender   Weight (g)   Animal model                                                                                  Dose                             Time periods                                     Mechanisms                                                                                                                                  References
  ------------------ ---------- -------- ------------ --------------------------------------------------------------------------------------------- -------------------------------- ------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------- ------------
  Asiatic acid       C57BL/6    male     22--27       pMCAO                                                                                         30, 75, and 165 mg/kg, i.g.      1 h before and 3, 10, and 20 h after pMCAO       Cyto-c↓, BBB permeability (IgG)↓                                                                                                            [@B53]
  Ginsenoside R~d~   SD         male     270--320     MCAO                                                                                          50 mg/kg, i.p.                   30 min before MCAO                               MMP↑, aconitase↑, mitochondrial complexes I-IV↑; ROS↓, lactate/pyruvate ratio↓, cleaved Caspase-3, Cyto-c↓, AIF↓                            [@B149]
  Genistein          C57/BL6J   male     24--28       MCAO (1 h)/R (24 h)                                                                           2.5, 5, and 10 mg/kg, i.g.       Pretreatment once daily for 2 w                  SOD↑, GSH-Px↑, mitochondrial Cyto-c↑; MDA↓, mtROS↓, cytosolic Cyto-c↓, Caspase-3↓, TUNEL-positive neurons↓, p-NF-κB p65 subunit↓, p-IκBα↓   [@B94]
  Oxysophoridine     ICR        male     20--25       MCAO (2 h)/R (24 h)                                                                           62.5, 125, and 250 mg/kg, i.p.   Pretreatment once daily for 1 w                  SOD↑, GSH-Px↑, Bcl-2↑; MDA↓, Caspase-3↓, Bax↓, TUNEL-positive neurons↓                                                                      [@B120]
  Echinacoside       SD         both     12--17       Permanent ligation of the left CCA plus low oxygen atmosphere (8% O~2~, 92% N~2~) for 2.5 h   40, 80, and 160 mg/kg, i.p.      Every 12 h after operation, a total of 4 times   SOD↑, GSH-Px↑, CAT↑, T-AOC↑, Bcl-2/Bax↑; MDA↓, Caspase-3↓, TUNEL-positive neurons↓                                                          [@B133]
  Gallic acid        SD         male     250--300     MCAO (2 h)/R (24 h)                                                                           25 and 50 mg/kg, i.v.            20 min before MCAO                               MMP↑, mitochondrial Cyto-c↑; MDA↓, ROS↓, cytosolic Cyto-c↓, TUNEL-positive neurons↓                                                         [@B109]
                     SD         male     250--300     MCAO                                                                                          50 mg/kg                                                                          binding capacity of CypD and ANT-1↓, MPTP openinng↓, p-ERK↓, Cyto-c↓, cleaved Caspase-3/8/9↓                                                [@B110]
  Oxymatrine         SD         both     ------       Permanent ligation of the left CCA plus low oxygen atmosphere (8% O~2~, 92% N~2~) for 2.5 h   30, 60, and 120 mg/kg, i.p.      Every 12 h after operation, a total of 2 times   SOD↑, GSH-Px↑, CAT↑, T-AOC↑, Bcl-2/Bax↑, MDA↓, Caspase-3↓, neuronal apoptosis under flow cytometry↓                                         [@B167]
  Matrine            ICR        male     20--25       MCAO (2 h)/R (24 h)                                                                           7.5, 15, and 30 mg/kg, i.p.      Pretreatment once daily for 1 w                  SOD↑, GSH-Px↑, CAT↑, T-AOC↑, Bcl-2/Bax↑, MDA↓, Caspase-3↓, neuronal apoptosis under flow cytometry↓                                         [@B168]
  Taurine            SD         both     ------       Permanent ligation of the left CCA plus low oxygen atmosphere (8% O~2~, 92% N~2~) for 2 h     30, 60, and 120 mg/kg, i.p.      Every 12 h after operation, a total of 2 times   SOD↑, GSH-Px↑, T-AOC↑, Bcl-2/Bax↑, ATP↑; LA↓; MPO↓, MDA↓, AIF↓, Cyto-c↓                                                                     [@B179]
  HSYA               Wistar     male     220--250     MCAO (1 h)/R (24 h)                                                                           8 mg/kg, i.v.                    After reperfusion                                GSH↑, CAT↑; MDA↓, TNF-α↓, MPTP opening↓                                                                                                     [@B95]
  Curcumin           Wistar     male     180--200     MCAO/R                                                                                        25 mg/kg, i.p.                                                                    Bcl-↑, Sirt1↑, MMP ↑; p53↓, Bax↓, IL-6↓, TNF-α↓, ROS↓                                                                                       [@B158]
  Picroside II       Wistar     male     240--260     MCAO (2 h)/R (24 h)                                                                           20 mg/kg, i.p.                   15 min before MCAO/R.                            VDAC1↓, cytoplasmic and nuclear EndoG↓, ROS↓, MPTP opening↓, TUNEL-positive neurons↓                                                        [@B64]
  Rhein              SD         male     260--300     MCAO (2 h)/R (72 h)                                                                           25, 50, and 100 mg/kg, i.g.      3 days following MCAO/R                          SOD↑, GSH-Px↑, CAT↑, Bcl-2/Bax ratio↑; MDA↓, Caspase-3/9↓, cleaved Caspase-3↓                                                               [@B173]
  Genipin            C57BL/6    male     25--30       MCAO (1 h)/R (24 h)                                                                           50 mg/kg, i.g.                   Pretreatment once daily for 3 d                  ATP↑, SOD↑, GSH↑; UCP2↓, SIRT3↓, NAD^+^/NADH↓, LDH↓, cleaved Caspase-3↓, TUNEL-positive neurons↓                                            [@B174]
  Swertiamain        ICR        male     20--25       MCAO (2 h)/R (24 h)                                                                           25, 100, and 400 mg/kg, i.p.     Pretreatment once daily for 1 w                  Bcl-2/Bax↑, SOD↑, GSH-Px↑, CAT↑, GSH↑, nulcear Nrf2↑, HO-1↑, NQO1↑; MDA↓, Keap1↓, cytoplasmic Nrf2↓, TUNEL-positive neurons↓                [@B126]

↑, upgrade; ↓, downgrade.

###### 

The *in vitro* mechanism underlying the inhibition of MPTP opening-induced neuronal apoptosis by monomeric compounds in the treatment of ischemic stroke.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Agents                           Cell lines                      Model                                                    Dose                        Time periods                                Mechanisms                                                                                                                                                                                   References
  -------------------------------- ------------------------------- -------------------------------------------------------- --------------------------- ------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------
  Asiatic acid                     HT-22                           OGD (5 h)/R (24 h)                                       1 and 10 µg/ml              Posttreatment for 24 h                      MMP↑, Cyto-c↓                                                                                                                                                                                [@B53]

  Tetrahydroxystilbene glucoside   PCN of neonatal SD rats         OGD (5% CO~2~ and 95% N~2~, 2 h)/R (24 h)                25 µM                       Pretreatment for 24 h                       MMP↑, SIRT1↑, Bcl-2/Bax↑; LDH↓, ROS↓, p-JNK↓, iNOS↓, nuclear p65↓, Ca^2+^↓, Hoechst 33258 positive staining↓                                                                                 [@B117]

  Mangiferin and\                  PCN of embryonic SD rats        50 μM glutamate plus 10 μM glycine                       1--10^4^ nM                 During and after glutamate\                 SOD↑, CAT↑, p-Akt↑, cytoplasmic p65↑, MMP↑;\                                                                                                                                                 [@B19]
  Morin                                                                                                                                                 exposure                                    Calpain↓, p-Erk1/2↓, nuclear p65↓, AIF↓, Bax↓, ROS↓                                                                                                                                          

  Trans resveratrol                PC12                            OGD (5% CO~2~, 94% N~2~, and 1% O~2~, 6 h)/R (24 h)      5, 10, and 25 μM            24 h before/post OGD                        Bcl-2↑, GSH↑; Bax↓, HIF-1α↓, Caspase-3↓, ROS↓, LPO↓                                                                                                                                          [@B2]

  Oxysophoridine                   PHN of neonatal SD rats         OGD (2 h)/R (24 h)                                       5, 20, and 80 μM            OGD (2 h)/R (24 h)                          Bcl-2/Bax↑; Caspase-3/8/9↓, Cyto-c↓, Hoechst-33342 fluorescence intensity↓\                                                                                                                  [@B23];\
                                                                                                                                                                                                    SOD↑, CAT↑, GSH-Px↑, MMP↑; NOS↓, glutamate↓, Ca^2+^↓, MDA↓, NO↓                                                                                                                              [@B166]

  Gallic acid                      SH-SY5Y                         Hypoxia (Na~2~S~2~O~4~, 2 h)/R (2 h)                     0.1, 1, and 10 μM           Pretreatment for 24 h                       MMP↑, ATP↑, oxygen consumption↑; MDA↓, intracellular ROS↓, mtROS↓, MPTP opening↓                                                                                                             [@B109]

                                   SH-SY5Y                         /                                                        0.1, 1, and 10 mM           24 h before H~2~O~2~-induced MPTP opening   binding capacity of CypD and ANT-1↓, MPTP openinng↓, p-ERK↓, Cyto-c↓, cleaved Caspase-3/8/9↓                                                                                                 [@B110]

  Oxysophocarpine                  PHN of neonatal SD rats         OGD (5% CO~2~, and 95% N~2~, 2 h)/R (24 h)               1, 2, and 5 μmol/L          During reperfusion period                   MMP↑; LDH↓, Ca^2+^↓, Caspase-3/12↓                                                                                                                                                           [@B178]

  Epicatechin and Quercetin        PCN of embryonic CD1 mice       OGD (5% CO~2~, 5% H~2~, and 90% N~2~, 5 min)/R (1.5 h)   0.1--10 μM                  Pretreatment for 24 h                       OCRs↑, p-Akt/Akt↑, p-CREB/CREB↑, Bcl-2↑, PGC-1a↑, MT-ND2 (complex I)↑, MT-ATP6 (complex V)↑, MMP↑; Ca^2+^↓, NOS↓                                                                             [@B85]

  Aloperine                        PHN of neonatal SD rats         OGD (5% CO~2~, and 95% N~2~, 2 h)/R (24 h)               25, 50, and 100 mg/L        During reperfusion period                   CAT↑, SOD↑, GSH-Px↑, T-AOC↑, MMP↑; LDH↓, Ca^2+^↓, MDA↓, ROS↓, Hoechst 33342 positive staining↓                                                                                               [@B75]

  Aloin                            PC12                            OGD (5% CO~2~, and 95% N~2~, 4 h)/R (24 h)               10, 20, and 40 μg/ml        During OGD/R period                         MMP↑, Bcl-2↑, SOD↑; LDH↓, MDA↓, ROS↓, Ca^2+^↓, Bax↓, Caspase-3↓, Hoechst 33342 positive staining↓, apoptosis under flow cytometry↓                                                           [@B22]

  Kaempferol                       PCN of 17-d embryonic rats      OGD (2 h)                                                10 μM                       Before OGD                                  OCRs↑, p-Akt/Akt↑, MMP↑, p-Drp1/Drp1↑, ATG5↑, ATP↑, HK-II↑, LC3 II/I ratios↑, mitochondrial Cyto-c/cytosolic Cyto-c↑; ROS↓, Ca^2+^↓, SDH↓, apoptosis under flow cytometry↓, MPTP openinng↓   [@B137]

  Dehydrocostuslactone             hippocampal slices of SD rats   OGD (5% CO~2~, and 95% N~2~, 0.5 h)/R (1 h)              1, 5, and 10 µM             During OGD/R period                         LC3 II/I ratios↑, Bcl-2↑; LDH↓, Bax↓, Cyto-c↓, Apaf-1↓, Caspase-3/7/9↓, p62↓                                                                                                                 [@B172]

  Icariside II                     PC12                            OGD (5% CO~2~, and 95% N~2~, 2 h)/R (24 h)               12.5, 25, and 50 μM         Posttreatment for 24 h                      nuclear Nrf2↑, NQO-1↑, HO-1↑, Bcl-2/Bax↑, SIRT3↑, IDH2↑~,~ MMP↑; LDH↓, ROS↓, cytoplasmic Nrf2↓, Keap1↓, cleaved Caspase-3↓, TUNEL-positive neurons↓                                          [@B39]

  Astragaloside IV                 PCN of 18-d embryonic SD rats   OGD (1% O~2~, 5% CO~2~, 3 h)/R (24 h)                    6.25, 12.5, and 25 μmol/L   During OGD/R period                         p-PKA/PKA and p-CREB/CREB↑, ATP↑, MMP↑; LDH↓, cleaved Caspase-3↓, ROS↓                                                                                                                       [@B144]

  Oxymatrine                       PHN of newborn SD rats          OGD (5% CO~2~ and 95% N~2~, 2 h)/R (24 h)                0.2, 1, and 5 µg/ml         During reperfusion period                   MCL-1↑, Bcl-2↑, p-Akt↑, p-PI3K↑, p-GSK3β↑, MMP↑; LDH↓, Ca^2+^↓, Caspase-3↓, NR2B↓ (NMDAR1), TUNEL-positive neurons↓, neuronal apoptosis under flow cytometry↓                                [@B70]

  Salvinorin A                     HBMECs                          OGD (5% CO~2~ and 95% N~2~, 6 h)/R (24 h)                5 uM                        During reperfusion period                   p-AMPK↑, Mfn2↑, ATP↑, MMP↑; ROS↓, Ca^2+^↓, apoptosis under flow cytometry↓                                                                                                                   [@B36]
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

↑, upgrade; ↓, downgrade.

*In vivo* and *in vitro* studies have shown that oxysophoridine could regulate Bcl-2 family members, and thereby counteracting mitochondria-mediated apoptosis. Meanwhile, it was possible to suppress Ca^2+^ overload of neurons and maintain mitochondrial MMP by anti-oxidative stress and inhibiting the toxicity of neuronal excitatory amino acids ([@B23]; [@B120]; [@B166]). Oxysophocarpine could also limit hypoxia-induced neuronal apoptosis by inhibiting Ca^2+^ and increasing MMP ([@B178]). Further studies have shown that the inhibitory effect of apoptosis was related to anti-inflammatory and down-regulation of MAPK signaling pathway ([@B170]). Similarly, aloperine ([@B75]), matrine, and oxymatrine ([@B167]; [@B168]; [@B70]) may have the same protective effect against ischemic neuron apoptosis. As a reversible selective inhibitor of true cholinesterase, huperzine A has been shown to inhibit mitochondrial complexes I--IV, a-ketoglutarate dehydrogenase, and MMP decline after ischemia, which helps to eliminating excessive ROS and Ca^2+^ ([@B175]). Considering the short *in vivo* half-life of tetramethylpyrazine, a novel compound containing tetramethylpyrazine and carnitine structures was synthesized. Further *in vivo* and *in vitro* results also confirmed that its anti-hypoxic brain protective effect was related to anti-oxidative stress and anti-inflammatory, ultimately maintaining the morphology and function of neurons and inhibiting neuronal apoptosis ([@B124]). Of course, there are other natural compounds that antagonize ischemia-infuriated morphological and functional disorders of brain mitochondria by regulating oxidative stress signals such as leonurine ([@B71]) and neferine ([@B139]).

Flavonoids resisting oxidative stress may drive the recovery of ischemia attacked neuron mitochondrial function, evidenced by increased mitochondrial biosynthesis and respiration, dampened Ca^2+^ production, and mitochondria edema, such as icariside II ([@B39]), as well quercetin and epicatechin in flavonols ([@B85]). As an Nrf2 activator, mangiferin inhibited the nuclear translocation of two subunits of NF-κB, p65 and p50, and the superior antioxidant properties of mangiferin and morin inhibited Ca^2+^ overload and improved mitochondrial MMP, thus counteracting the lethal post-ischemic neuronal excitatory toxic damage and cascade apoptosis ([@B19]). Other reports suggested that the protective effects of genistein ([@B94]), isorhamnetin ([@B62]), and vitexin ([@B31]) against ischemia may involve both inflammation and inhibition of neuronal apoptosis. Most terpenoids also have antioxidant properties similar to those of alkaloids and flavonoids, which helped maintain mitochondrial morphology and respiratory function as well as ischemia-induced neuronal apoptosis, such as bilobalide ([@B98]) and Swertiamain ([@B126]). Studies have shown that the treatment time window of asiatic acid can be maintained for at least 12 h, which is related to the improvement of MMP and the inhibition of mitochondrial Cyto-c release ([@B53]). The balanced redox effect of ginsenoside Rd may contribute to the improvement of cerebral injury symptoms ([@B148]). Further evidence showed that Rd could improve mitochondrial respiratory function and increase ATP production by reducing ROS production, thereby maintaining MMP and inhibiting neuronal apoptosis ([@B149]), which was similar to dehydrocostuslactone's protection of rat hippocampal slices from OGD/R-induced damage ([@B172]). Astragalosides IV may maintain mitochondrial function and inhibit OGD/R-induced cortical neuronal apoptosis by regulating PKA/CREB signaling pathway ([@B144]). *In vivo* and *in vitro* evidence suggested that Salvinorin A played an anti-apoptotic and anti-hypoxia protective role in brain involving the reduction of ROS and Ca^2+^ production in cerebrovascular endothelial cells, the activation of AMPK/Mfn2 signaling pathway, and ultimately maintenance of mitochondrial morphology and MMP ([@B36]). As an excellent natural biological cross-linking agent and a specific inhibitor of mitochondrial uncoupling protein 2 (UCP2), *in vivo* studies have shown that genipin could improve mitochondrial energy metabolism by inhibiting UCP2-SIRT3 signaling pathway to mitigate oxidative stress injury and neuronal apoptosis after hypoxic brain injury ([@B174]).

Other compounds such as taurine ([@B179]) and echinacoside ([@B133]) could also regulate Bcl-2 family members through antioxidant stress, and inhibit mitochondrial apoptosis to improve hypoxic brain injury. Ischemic brain protection against neuronal apoptosis of phenolic acid compounds tetrahydroxystilbene glucoside ([@B117]), vanillin ([@B56]), curcumin ([@B158]), and apocynin ([@B30]) may also further involved in the mechanism of anti-inflammatory, such as regulating the NF-κB and JNK, or targeting SIRT1. The antioxidant activity of quinones shikonin ([@B118]) and aloin ([@B22]), with a similar anti-cerebral ischemia action of rhein in our previous study ([@B173]), as well as phenylpropanoid compounds cinnamtannin D1 and trans-cinnamaldehyde ([@B89]; [@B93]) from cinnamon might reduce the accumulation of Ca^2+^ and ROS, thus improving MMP to exert anti-ischemic neuron apoptosis. Through the above analysis of officially authorized drugs for the treatment of ischemic stroke, ethnic drug prescription, herbs, and monomer components, we found that most of them have the effect of anti-oxidative stress. The inhibition of overloaded Ca^2+^ and overproduced mtROS is the premise of drugs to reverse the decline of MMP after ischemia, improve mitochondrial respiratory function, and maintain the ATP supply of neurons. Although apoptosis might be the ultimate destination of neurons after ischemic stroke, we are pleasantly surprised to find that many adverse factors after ischemia might drive mitochondrial MPTP overopening. Meanwhile, we have previously discussed some potential proteins or oligomers that may be involved in regulating MPTP opening after cellular hypoxia, such as Bcl-2, Bax, Bcl-xL, and oligomer Bax/Bak of the Bcl-2 family. Through reviewing literatures, we also found that the above natural products could directly or indirectly inhibit MPTP overopening after ischemia. Furthermore, increased OMM permeability and collapsed mitochondrial membrane structures are inhibited. Ultimately, the integrity of the mitochondrial membrane and MMP are rescued, thus inhibiting the vicious cycle of excessive Ca^2+^ and mtROS production. As seen from the end results, caspase-dependent apoptosis triggered by the release of mitochondrial contents such as Cyto-c and AIF was blocked. Collectively, we have reason to believe that mitochondrial MPTP may be a potential target of natural products to inhibit neuronal apoptosis in treatment of ischemic stroke. Among the mechanisms, there may also be inflammation and oxidative stress signaling involved in MPTP opening and apoptosis. We summarized the mechanisms by which ethnic drugs may regulate MPTP to inhibit apoptosis of ischemic neurons, as shown in [**Figure 4**](#f4){ref-type="fig"}. Among them, the mechanisms that have not been reported and elucidated still need to be further probed.

![A panoramic view of natural products inhibiting MPTP opening-induced neuronal apoptosis in the treatment of ischemic stroke. Any adverse stimuli after ischemic stroke could favor MPTP opening. However, natural products that inhibit MPTP opening could further prevent neuronal inflammation after ischemia, oxidative stress injury, and mitophagy, and finally repress ischemic neuron apoptosis.](fphar-11-00352-g004){#f4}

Conclusion and Future Prospects {#s3}
===============================

The literatures on targeted improvement of mitochondrial MPTP by ethnic medicine were reviewed systematically and purposefully. We were ecstatic to accept the trend that balanced mitochondrial MPTP was becoming a novel strategy for drug treatment of stroke ([@B15]). First, we identified that the process of stroke was associated with an abnormal over-opening of mitochondrial MPTP. Any factors that induced insufficient blood supply to the brain may lead to robust ROS, unbalanced intracellular Ca^2+^ homeostasis, decrease MMP, inflammation, and ERS. These detrimental events were doomed to be fatal to mitochondria and initiate changes in the three-dimensional conformation of mitochondrial MPTP, which would in turn aggravate the production of mitochondrial ROS, mitochondrial edema, the booming cytoplasmic Ca^2+^, the decline of MMP, and the reduction of ATP synthesis. To sum up, all these adverse biological events that caused the loss of the function of mitochondrial bilayer barrier would inevitably disrupt the material transfer between mitochondrial matrix and cytoplasm. Consequently, the activated mitochondrial dependent apoptosis was triggered according to an inherent set of biological procedures. And this process was regularly and strictly executed by mitochondria-emitted apoptosis signal, and delivered step by step. For instance, ischemia-induced MPTP opening leaded to the translocation of Cyto-c from mitochondrial matrix into cytoplasm, and binding with Apaf-1 and Caspase-9 to form apoptosome, thereby activating caspase-dependent programmed cell death pathways in ischemic/anoxic neurons. Secondly, we found piece by piece that ethnic drug prescriptions, herbal medicine, and monomer components could participate in regulation of excessive MPTP opening induced-ischemic neuronal apoptosis from different perspectives. We therefore concluded that mitochondrial MPTP, a very considerably intermediate link in apoptosis signaling, might be a novel target for natural products in treatment of stroke.

However, by weighing the pros and cons, the following aspects should be worthy to further optimization considering the anti-apoptotic brain protection effect of ethnic drugs through regulation of mitochondrial MPTP. First, the complexity and uncertainty of active ingredients penetrating blood brain barrier (BBB). Current methods for identifying active ingredients included high performance liquid chromatography (HPLC), mass spectrum, gas chromatography-mass spectrometer (GC-MS), or liquid chromatograph-mass spectrometer (LC-MS). However, the key problem lay in the selection and preprocessing of samples for content determination: the original herbs or prescription extracted by simple decoction, ultrasound or different proportions of organic reagents, animal serum or brain tissue homogenate after administration. Any test based on those ideas would simply identify specific monomer compounds contained in certain prescriptions or extracts. However, the premise of drug efficacy was to achieve a certain concentration in target organs or tissues such as specific brain regions to stimulate the transmission of anti-apoptotic protective signals. Slightly regretfully, the qualitative or quantitative identification methods mentioned above cannot completely represent the concentration of drug enrichment in cerebral ischemic regions. For this existing and confronting problems, we proposed that a microdialysis device coupled HPLC/MS would be a potential platform for screening active ingredients ([@B96]) or changeable pH value of brain microenvironment ([@B107]). Moreover, distribution concentrations of different small molecule drugs targeting distinct brain regions could be dynamically presented in real time and *in vivo* by an integrated platform of high resolution laser confocal microimaging coupled with brain MS imaging ([@B43]; [@B69]). Finally, a multi-dimensional image of drug distribution in brain tissue was visually and stereoscopically constructed. Second, the rationality of *in vivo* and *in vitro* simulation of clinical stroke model in light of the complexity of BBB tissue structure ([@B111]). Currently, diverse *in vivo* stroke models for cerebral ischemia, or *in vitro* OGD/R-induced hippocampal slices or different neuron injury models, which were widely accepted and acquiescent, cannot reproduce the scene of changes in brain tissue structure and the specific molecular-mediated damage mechanisms yet. Therefore, the above existing stroke models needed to be further discussed. However, it was encouraging to note that our research group had successfully established *in vitro* co-culture models of cerebrovascular endothelial cell, astrocytes, and pericytes to simulate BBB (the data have not yet been published), referring to the organ-like models of multiple neurons co-culture or BBB previously reported ([@B9]). Of course, through establishment of *in vitro* neurovascular unit (NVU), we also strived to achieve real-time and rapid evaluation of natural small molecule compounds passing BBB, and to screen the quality markers of ethnic drugs and functional protein targets on a coupled microfluidic chip-mass spectrometry (MC-MS) platform ([@B129]).

Third, the mechanisms of small molecular compounds acting on mitochondrial MPTP to inhibit apoptosis after ischemic stroke were unsophisticated. According to what we have learned, the conventional means demonstrating the interrelationship between drugs and MPTP were limited to the following. After intervention with MPTP inhibitors or agonists, conventional western blot, immunohistochemistry/fluorescence ([@B12]), flow cytometry, and qRT-PCR were employed to evaluate the effect of drugs on changes in protein and gene expression that made up MPTP, such as VDAC and ANT. In addition, gene editing such as plasmids or viruses transfection of target gene vectors to overexpress or silence the target gene, or to completely knock out or down the target gene and observe the effect of drugs on MPTP were also some popular molecular biology methods. Certain proteins or protein complexes such as Bax/Bak dimerization, mtROS, oxidative stress, and inflammatory factors could regulate MPTP opening-induced cell apoptosis, thus providing indirect evidence for drug regulation of MPTP. The more intuitive evidence might be to detect some of triggering hallmarks after MPTP opening, such as mitochondrial swelling, decreased MMP and ATP production, and detection of fluorescent labeled cytoplasmic Ca^2+^ surge. However, none of the above methods could provide direct evidence of drug-MPTP-apoptosis. That is, it cannot be visualized that drugs confined MPTP opening, and thus inhibiting cell apoptosis. The deficiencies of the above mechanisms investigation included the limited understanding of MPTP and the limitations of current molecular imaging technologies. Therefore, more efforts were needed to explore the molecular basis and regulatory mechanism of MPTP. We also had reason to believe that the laser confocal high intentionality live cell real-time imaging and analysis system would be a robust alternative for probing drug targeted regulation of MPTP. Moreover, patch-clamp combined with two-photon living cell imaging technology also had potential prospects for detection of prophylaxis and treatment of ethnic drugs on post-stroke mitochondrial MMP and Ca^2+^ or other ion levels ([@B52]; [@B136]; [@B163]). In conclusion, we were optimistic that abnormal opening of mitochondrial MPTP-induced apoptosis would become a potential target for stroke treatment by ethnic medicine. Further, we conceived and constructed the systematic process and program of drugs regulating mitochondrial MPTP to inhibit apoptosis in ischemic stroke, as shown in [**Figure 5**](#f5){ref-type="fig"}. However, objectively speaking, no matter how many preclinical investigations were merely paving the way for screening mitochondrial MPTP targeted candidates, clinical trials with large samples and multi-center joint evaluation of the clinical efficacy of candidates were still necessary to be carried out.

![Conceptual flowchart of combined multiple techniques for MPTP regulation by natural products on apoptosis of ischemic neurons. Mitochondrial MPTP is a novel target for the treatment of ischemic stroke. Determination of the distribution of natural products in distinct brain regions, reasonable *in vivo* and *in vitro* stroke models, and advanced MPTP imaging technologies will be conducive to the development of ethnic drugs targeting MPTP.](fphar-11-00352-g005){#f5}
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